516 related articles for article (PubMed ID: 24441663)
41. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
42. Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.
Vocke CD; Ricketts CJ; Merino MJ; Srinivasan R; Metwalli AR; Middelton LA; Peterson J; Yang Y; Linehan WM
Genes Chromosomes Cancer; 2017 Jun; 56(6):484-492. PubMed ID: 28196407
[TBL] [Abstract][Full Text] [Related]
43. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.
Harrison WJ; Andrici J; Maclean F; Madadi-Ghahan R; Farzin M; Sioson L; Toon CW; Clarkson A; Watson N; Pickett J; Field M; Crook A; Tucker K; Goodwin A; Anderson L; Srinivasan B; Grossmann P; Martinek P; Ondič O; Hes O; Trpkov K; Clifton-Bligh RJ; Dwight T; Gill AJ
Am J Surg Pathol; 2016 May; 40(5):599-607. PubMed ID: 26574848
[TBL] [Abstract][Full Text] [Related]
44. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
45. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.
Gardie B; Remenieras A; Kattygnarath D; Bombled J; Lefèvre S; Perrier-Trudova V; Rustin P; Barrois M; Slama A; Avril MF; Bessis D; Caron O; Caux F; Collignon P; Coupier I; Cremin C; Dollfus H; Dugast C; Escudier B; Faivre L; Field M; Gilbert-Dussardier B; Janin N; Leport Y; Leroux D; Lipsker D; Malthieu F; McGilliwray B; Maugard C; Méjean A; Mortemousque I; Plessis G; Poppe B; Pruvost-Balland C; Rooker S; Roume J; Soufir N; Steinraths M; Tan MH; Théodore C; Thomas L; Vabres P; Van Glabeke E; Meric JB; Verkarre V; Lenoir G; Joulin V; Deveaux S; Cusin V; Feunteun J; Teh BT; Bressac-de Paillerets B; Richard S;
J Med Genet; 2011 Apr; 48(4):226-34. PubMed ID: 21398687
[TBL] [Abstract][Full Text] [Related]
46. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma.
Udager AM; Alva A; Chen YB; Siddiqui J; Lagstein A; Tickoo SK; Reuter VE; Chinnaiyian AM; Mehra R
Am J Surg Pathol; 2014 Apr; 38(4):567-77. PubMed ID: 24625422
[TBL] [Abstract][Full Text] [Related]
47. Fumarate Hydratase and S-(2-Succinyl)-Cysteine Immunohistochemistry Shows Evidence of Fumarate Hydratase Deficiency in 2% of Uterine Leiomyosarcomas: A Cohort Study of 348 Tumors.
Chapel DB; Sharma A; Maccio L; Bragantini E; Zannoni GF; Yuan L; Quade BJ; Parra-Herran C; Nucci MR
Int J Gynecol Pathol; 2023 Mar; 42(2):120-135. PubMed ID: 36729957
[TBL] [Abstract][Full Text] [Related]
48. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
Plevová P; Hladíková A; Tesařová M
Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
[TBL] [Abstract][Full Text] [Related]
49. Novel missense mutation in the FH gene in familial renal cell cancer patients lacking cutaneous leiomyomas.
Kuwada M; Chihara Y; Lou Y; Torimoto K; Kagebayashi Y; Tamura K; Shuin T; Fujimoto K; Kuniyasu H; Samma S
BMC Res Notes; 2014 Mar; 7():203. PubMed ID: 24684806
[TBL] [Abstract][Full Text] [Related]
50. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
51. Fumarate hydratase immunohistochemical staining may help to identify patients with multiple cutaneous and uterine leiomyomatosis (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome.
Llamas-Velasco M; Requena L; Kutzner H; Schärer L; Rütten A; Hantschke M; Paredes BE; Mentzel T
J Cutan Pathol; 2014 Nov; 41(11):859-65. PubMed ID: 25292446
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
[TBL] [Abstract][Full Text] [Related]
53. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A
Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
[TBL] [Abstract][Full Text] [Related]
54. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
[TBL] [Abstract][Full Text] [Related]
55. Increased risk of cancer in patients with fumarate hydratase germline mutation.
Lehtonen HJ; Kiuru M; Ylisaukko-Oja SK; Salovaara R; Herva R; Koivisto PA; Vierimaa O; Aittomäki K; Pukkala E; Launonen V; Aaltonen LA
J Med Genet; 2006 Jun; 43(6):523-6. PubMed ID: 16155190
[TBL] [Abstract][Full Text] [Related]
56. Prevalence of somatic and germline mutations of Fumarate hydratase in uterine leiomyomas from young patients.
Liu C; Dillon J; Beavis AL; Liu Y; Lombardo K; Fader AN; Hung CF; Wu TC; Vang R; Garcia JE; Xing D
Histopathology; 2020 Feb; 76(3):354-365. PubMed ID: 31564060
[TBL] [Abstract][Full Text] [Related]
57. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes.
Carter CS; Skala SL; Chinnaiyan AM; McHugh JB; Siddiqui J; Cao X; Dhanasekaran SM; Fullen DR; Lagstein A; Chan MP; Mehra R
Am J Surg Pathol; 2017 Jun; 41(6):801-809. PubMed ID: 28288038
[TBL] [Abstract][Full Text] [Related]
59. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
60. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
